Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052)

J Infect Dis. 2013 Nov 15;208(10):1624-8. doi: 10.1093/infdis/jit390. Epub 2013 Aug 1.

Abstract

The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to self-report of ARV drug use in some clinical trial settings.

Keywords: Africa; HIV; HPTN 052; antiretroviral drug; clinical trial; self-report.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • Humans
  • Male
  • Risk Factors
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents